

Press release

Ackermans & van Haaren supports
MRM Health's Series B financing
round of 55 million euros



ACKERMANS & VAN HAAREN

Your partner for sustainable growth



Antwerp,
September 4, 2025, 07:15 h CET

Regulated information within the meaning
of the Royal Decree of November 14, 2007.

Ackermans & van Haaren supports MRM Health's Series B financing round of 55 million euros

Ackermans & van Haaren (AvH) supports the Series B financing round totaling 55 million euros of MRM Health, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology.

The successful closing of this Series B financing round was announced earlier this morning by MRM Health ([MRM Health - redefining microbiome therapeutics](#)).

The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and – in addition to AvH – existing investors SFPIM, OMX Europe Venture Fund (OMX), Qbic II and VIB.

Proceeds from the financing will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on rationally designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical data in Phase 2a trials showing safety and initial efficacy in both mild-to-moderate ulcerative colitis and in the orphan disease indication pouchitis.

MRM Health has also ongoing preclinical programs in other inflammatory diseases and in immune oncology.

For AvH, this series B financing round involves an additional investment of 3 million euros and brings its total investment in MRM Health to 10.8 million euros and its fully diluted participation to 14.1% (from 15.5%).

Jens Van Nieuwenborgh, Investment director at AvH and board member of MRM Health, comments: “The unmet medical need in inflammatory bowel diseases remains high. MH002 is one of the very few microbiome products that has demonstrated promising clinical benefit in clinical trials for both ulcerative colitis and pouchitis. We are excited to contribute to the continued journey of bringing this promising therapy to the more than 5 million patients suffering from these diseases.”

Piet Dejonghe, co-CEO AvH states: “We are happy to support MRM Health in this hallmark financing round in the microbiome field. This validates MRM Health's leadership in the development of microbiome-based therapeutics for patients with chronic inflammatory diseases. The strategic partnership with Biocodex further pays tribute to the unique capabilities MRM Health has built with its CORAL® technology platform.”

Ackermans & van Haaren

Ackermans & van Haaren positions itself as the long-term partner of choice of family businesses and management teams to help build high-performing market leaders and contribute to a more sustainable world.

Ackermans & van Haaren is a diversified group operating in 4 core sectors: Marine Engineering & Contracting (DEME, one of the largest dredging companies in the world – CFE, a construction group with headquarters in Belgium). Private Banking (Delen Private Bank, one of the largest independent private asset managers in Belgium, and asset manager JM Finn in the UK - Bank Van Breda, niche bank for entrepreneurs and the liberal

professions in Belgium). Real Estate (Nextensa, a listed integrated real estate group) and Energy & Resources (SIPEF, an agro-industrial group in tropical agriculture). In its Growth Capital segment, AvH also provides growth capital to sustainable companies in different sectors.

At an economic level, the AvH group represented in 2024 a turnover of 7.6 billion euros, on which it realized a net profit of 460 million euros, and employed 24,384 people through its share in the portfolio companies. AvH is listed on Euronext Brussels and is included in the BEL20 index, the BEL ESG index, the MSCI Europe Small Cap index and the European DJ Stoxx 600 index.

Website

All press releases issued by AvH and its most important group companies as well as the 'Investor Presentation' can also be consulted on the AvH website: www.avh.be. Anyone who is interested in receiving the press releases via email has to register to this website.

Financial calendar

- November 21, 2025 Interim statement Q3 2025

Contact

For further information please contact:

John-Eric Bertrand
co-CEO - co-Chairman executive committee - Tel. +32.3.897.92.08

Piet Dejonghe
co-CEO - co-Chairman executive committee - Tel. +32.3.897.92.36

Tom Bamelis
CFO - Member executive committee - Tel. +32.3.897.92.35

e-mail: dirsec@avh.be

